source
- Novo to pay Hengrui up to $2.6 billion for rights to weekly obesity pill HRS-1596Novo announced a deal with China-based Hengrui Pharma, paying $300 million up front for rights to HRS-1596, a once‑weekly obesity pill. The agreement could rise to $2.6 billion if the candidate me…
- Ascletis pursues oral IL-17A inhibitor for psoriasis as Invivyd readies COVID-19 filingAscletis, a biotech listed in Hong Kong, is developing a small‑molecule IL-17A inhibitor in pill form to treat psoriasis. The company aims to challenge the current injectable therapies that target…